Main Article Content

Authors

Background: Tuberculin skin test (TST)  has an important place in the diagnosis of , latent tuberculosis infection (LTBI) for nearly a century


Objective: This study aimed to investigate the general characteristics of patients that were tested with TST in a university hospital within two years.


Methods: Patients that were tested with TST were included study. The Mantoux method was used for the administration of TST. All patients were assessed with regards to LTBI.


Results: A total of 661 patients, 345 (52.2%) men and 316 (47.8%) women, with a mean age of 43.0±15.9 years, were included in the study. Accordingly, TST was performed prior to anti-TNF biological agent therapy for 50% (331) of the participants, for LTBI screening before solid organ and/or hematological stem cell transplantation for 20.4% (135), for screening following contact with tuberculosis for 25.1% (166), for screening of healthcare professionals for 1.1% (7), and for medical report for 3.3% (22). 2.7% of the patients who took TST were diagnosed with active tuberculosis (14 with pulmonary tuberculosis and 4 with extrapulmonary tuberculosis). QuantiFERON-TB Gold (QFT)  test was performed in 332 (50.2%) patients with anergic TST results. According to TST and QFT test results, 28.3% (187) of the patients were started on tuberculosis prophylaxis.


Conclusion: While TST is most commonly performed for LTBI screening prior to biological agent therapy, almost one fourth of patients taking TST require tuberculosis prophylaxis. About half of the patients, on the other hand, require an additional QFT test.

Omer Yesil, MD, Akdeniz University

orcid_id14.png https://orcid.org/0000-0003-3800-9126

Yasin Gokmen, MD, Akdeniz University

orcid_id14.png https://orcid.org/0000-0002-5572-8475

Fatih Üzer, Akdeniz University Hospital

orcid_id14.png https://orcid.org/0000-0001-9318-0458

Sukriye Oner, MD, Akdeniz University

orcid_id14.png https://orcid.org/0000-0003-4563-3250

Tülay Ozdemir, Professor, Akdeniz University

orcid_id14.png 0000-0002-7012-3298

Yesil, O., Gokmen, Y., Üzer, F., Oner, S., & Ozdemir, T. (2023). The clinical utility of tuberculin skin tests: a single-center experience. Colombia Medica, 53(3), e–2015055. https://doi.org/10.25100/cm.v53i3.5055 (Original work published October 21, 2022)

Global tuberculosis report 2020. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO. Accessed September 1, 2021. https://www.who.int/publications-detail-redirect/9789240013131

Türkiye’de Verem Savaşı 2020 Raporu, T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü, Yayın no: 1205, Ankara, 2021. Accessed October 7, 2022. https://hsgm.saglik.gov.tr/tr/tuberkuloz-haberler/turkiye-de-verem-savasi.html

Özkara Ş, Kılıçaslan Z. Tüberküloz. AVES yayıncılık. Istanbul, 2010; 11:36-47

No authors listed. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161(4 Pt 2):S221-247. doi:10.1164/ajrccm.161.supplement_3.ats600

Zevallos K, Vergara KC, Vergara A, Vidal C, Garcia HH, Evans CA. Tuberculin Skin-Test Reactions Are Unaffected by the Severity of Hyperendemic Intestinal Helminth Infections and Co-Infections. Am J Trop Med Hyg. 2010; 83(2): 319-325. doi:10.4269/ajtmh.2010.10-0073

Gümüşlü F, Özkara Ş, Özkan S, Baykal F, Güllü Ü. Türkiyede verem Savaşı 2007 raporu. Verem Savaş Daire Başkanlığı Ankara 2007.

Tüberküloz tanı ve tedavi rehberi. T.C Sağlık Bakanlığı (Yayın no: 1129); Ankara, 2019.

Hanta I, Ozbek S, Kuleci S, Kocabas A. The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients. Clin Rheumatol. 2008;27(9):1083-1086. doi:10.1007/s10067-008-0867-3

WHO. Latent tuberculosi sinfection (Executive summary). Updated and consolidated guidelines for programmatic management. Geneva. World Health Organization; 2018. Accessed September 3, 2021. Available from: https://www.who.int/tb/publications/2018/executivesummary_consolidated_guidelines_ltbi.pdf?ua=

Acar M, Sütçü M, Salman N, Somer A. The Risk of Tuberculosis and TNF-alpha Inhibitors. J Pediatr Inf 2017; 11(2): e71-e75. Doi: 10.5578/ced.201719.

Anti-TNF Kullanan Hastalarda Tüberküloz Rehberi. T.C Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu.Ankara; 2016.

Pyo J, Cho SK, Kim D, Sung YK. Systemic review: agreement between the latent tuberculosis screening tests among patients with rheumatic diseases. Korean J Intern Med. 2018;33(6):1241-1251. doi:10.3904/kjim.2016.222

Dogan C, Kiral N, Comert SS, Fidan A, Caglayan B, Salepci B. Tuberculosis Frequency in Patients Taking TNF-alpha Blokers. Tur Toraks Der. 2012;13(3):93-98. doi:10.5152/ttd.2012.22

Manuel O, Humar A, Preiksaitis J, Doucette K, Shokoples S, Peleg AY, et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant. 2007;7(12):2797-2801. doi:10.1111/j.1600-6143.2007.02011.x

Malhotra KK, Dash SC, Dhawan IK, Bhuyan UN, Gupta A. Tuberculosis and renal transplantation--observations from an endemic area of tuberculosis. Postgrad Med J. 1986;62(727):359-362. doi:10.1136/pgmj.62.727.359

Roth PJ, Grim SA, Gallitano S, Adams W, Clark NM, Layden JE. Serial testing for latent tuberculosis infection in transplant candidates: a retrospective review. Transpl Infect Dis. 2016;18(1):14-21. doi:10.1111/tid.12489

Muñoz P, Rodríguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis. 2005;40(4):581-587. doi:10.1086/427692

Ahmadinejad Z, Azmoudeh AF, Razzaqi M, Davoudi S, Jafarian A. QuantiFERON-TB Gold In-Tube test for diagnosis of latent tuberculosis (TB) infection in solid organ transplant candidates: a single-center study in an area endemic for TB. Transpl Infect Dis. 2013; 15(1): 90-95. doi:10.1111/tid.12027

Horsburgh CR, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med. 2011; 364(15): 1441-1448. doi:10.1056/NEJMcp1005750

Barnes PF. Diagnosing latent tuberculosis infection: turning glitter to gold. Am J Respir Crit Care Med. 2004;170(1):5-6. doi:10.1164/rccm.2404004

Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep. 2010;59(RR-5):1-25.

Lee JE, Kim HJ, Lee SW. The clinical utility of tuberculin skin test and interferon-γ release assay in the diagnosis of active tuberculosis among young adults: a prospective observational study. BMC Infect Dis. 2011; 11(96):1-7. doi:10.1186/1471-2334-11-96

Ozcirpici B, Aydin N, Coskun F, Tuzun H, Ozgur S. Vaccination coverage of children aged 12-23 months in Gaziantep, Turkey: comparative results of two studies carried out by lot quality technique: what changed after family medicine? BMC Public Health. 2014; 14: 217. doi:10.1186/1471-2458-14-217

Horsburgh CRJ. Priorities for the treatment of latent tuberculosis infection in the United. N Engl J Med 2004;350:2060-7. doi: 10.1056/NEJMsa031667

Downloads

Download data is not yet available.
Received 2021-09-28
Accepted 2022-10-12
Published 2023-05-19